Related Experiment Video
Updated: May 22, 2026

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
Published on: June 19, 2019
Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial
P Hoever1, G Dorffner, H Beneš
1Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.
Abstract:
The orexin system is a key regulator of sleep and wakefulness. In a multicenter, double-blind, randomized, placebo-controlled, two-way crossover study, 161 primary insomnia patients received either the dual orexin receptor antagonist almorexant, at 400, 200, 100, or 50 mg in consecutive stages, or placebo on treatment nights at 1-week intervals. The primary end point was sleep efficiency (SE) measured by polysomnography; secondary end points were objective latency to persistent sleep (LPS), wake after sleep onset (WASO), safety, and tolerability. Dose-dependent almorexant effects were observed on SE , LPS , and WASO . SE improved significantly after almorexant 400 mg vs. placebo (mean treatment effect 14.4%; P < 0.001). LPS (–18 min (P = 0.02)) and WASO (–54 min (P < 0.001)) decreased significantly at 400 mg vs. placebo. Adverse-event incidence was dose-related. Almorexant consistently and dose-dependently improved sleep variables. The orexin system may offer a new treatment approach for primary insomnia.
Insights
Almorexant, a dual orexin receptor antagonist, significantly improved sleep efficiency and reduced sleep latency in primary insomnia patients. This study suggests the orexin system offers a promising new treatment for insomnia.
Area of Science:
- Neuroscience
- Sleep Medicine
Background:
- The orexin system critically regulates sleep-wake cycles.
- Primary insomnia is a prevalent sleep disorder with significant impact on quality of life.
Purpose of the Study:
- To evaluate the efficacy and safety of almorexant, a dual orexin receptor antagonist, in treating primary insomnia.
- To assess the dose-dependent effects of almorexant on sleep parameters.
Main Methods:
- A multicenter, double-blind, randomized, placebo-controlled, two-way crossover study.
- 161 primary insomnia patients received almorexant (50-400 mg) or placebo in 1-week intervals.
- Sleep efficiency (SE), latency to persistent sleep (LPS), and wake after sleep onset (WASO) were measured by polysomnography.
Main Results:
- Almorexant demonstrated dose-dependent improvements in SE, LPS, and WASO.
- Significant improvement in SE (14.4%) and reduction in LPS (–18 min) and WASO (–54 min) were observed at 400 mg compared to placebo.
- Adverse event incidence was dose-related.
Conclusions:
- Almorexant consistently and dose-dependently improved key sleep variables in patients with primary insomnia.
- The orexin system presents a potential novel therapeutic target for primary insomnia treatment.
More Related Videos
Related Concept Videos
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
REM Sleep Behavior Disorder
RBD is significantly associated with...
Narcolepsy
Understanding Sleep
The circadian rhythm, a nearly 24-hour cycle, is deeply influenced by environmental light cues. Light exposure directly affects the hypothalamus, which in turn regulates...

